T1	Participants 91 134	patients with metastatic colorectal cancer.
T2	Participants 136 242	One hundred twenty-two chemotherapy-naive patients with histologically confirmed colorectal adenocarcinoma
T3	Participants 1509 1552	patients with advanced colorectal carcinoma
